Table 4 Genotype distribution of patients using oxycodone
ABCB1(062rs1045642,C > T) | CYP3A5*3(058rs776746,A > G) | ||||||||||||||||
Group | CC | CT | TT | p | C | T | p | Group | AA | AG | GG | p | A | G | p | ||
Experience group | n | 3 | 20 | 9 | 0.020 | 26 | 38 | 0.018 | Experience group | n | 15 | 16 | 1 | 0.330 | 46 | 18 | 0.451 |
% | 9.38% | 62.50% | 28.13% | 40.63% | 59.38% | % | 46.88% | 50.00% | 3.13% | 71.88% | 28.12% | ||||||
Control group | n | 21 | 9 | 2 | 51 | 13 | Control group | n | 18 | 11 | 3 | 47 | 17 | ||||
% | 65.63% | 28.13% | 6.25% | 79.69% | 20.31% | % | 56.25% | 34.38% | 9.38% | 73.44% | 26.56% | ||||||
CYP2D6*10(008rs1065852,C > T) | OPPM1(047rs1799971,A > G) | ||||||||||||||||
Group | CC | CT | TT | p | C | T | p | Group | AA | AG | GG | p | G | A | p | ||
Experience group | n | 8 | 12 | 12 | 0.700 | 28 | 36 | 0.018 | Experience group | n | 12 | 16 | 4 | 0.710 | 40 | 24 | 0.770 |
% | 25.00% | 37.50% | 37.50% | 43.75% | 56.25% | % | 37.50% | 50.00% | 12.50% | 62.50% | 37.50% | ||||||
Control group | n | 10 | 13 | 9 | 51 | 13 | Control group | n | 16 | 11 | 5 | 43 | 21 | ||||
% | 31.25% | 40.63% | 28.13% | 79.69% | 20.31% | % | 50.00% | 34.38% | 15.63% | 67.19% | 32.81% | ||||||